AUROPHARMA:NSE:NSE-Aurobindo Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1241.1

Change

-2.10 (-0.17)%

Market Cap

USD 733.69B

Volume

0.67M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+10.70 (+0.72%)

USD 3,520.42B
DIVISLAB:NSE Divi's Laboratories Limited

+19.75 (+0.44%)

USD 1,204.18B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-8.60 (-0.80%)

USD 1,116.46B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+23.45 (+0.39%)

USD 1,006.15B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-10.00 (-0.35%)

USD 958.22B
MANKIND:NSE Mankind Pharma Ltd

-36.80 (-1.70%)

USD 877.19B
LUPIN:NSE Lupin Limited

-7.90 (-0.50%)

USD 711.68B
ALKEM:NSE Alkem Laboratories Limited

+86.95 (+1.74%)

USD 599.09B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-6.50 (-0.53%)

USD 347.26B
AJANTPHARM:NSE Ajanta Pharma Limited

+2.15 (+0.09%)

USD 294.04B

ETFs Containing AUROPHARMA:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.90% 61% D- 57% F
Dividend Return 0.14% 13% F 8% B-
Total Return 15.04% 62% D 57% F
Trailing 12 Months  
Capital Gain 77.52% 77% C+ 70% C-
Dividend Return 0.64% 36% F 42% F
Total Return 78.16% 76% C+ 70% C-
Trailing 5 Years  
Capital Gain 106.01% 27% F 34% F
Dividend Return 3.61% 41% F 35% F
Total Return 109.62% 27% F 34% F
Average Annual (5 Year Horizon)  
Capital Gain 28.80% 46% F 44% F
Dividend Return 29.52% 46% F 44% F
Total Return 0.72% 70% C- 55% F
Risk Return Profile  
Volatility (Standard Deviation) 58.46% 42% F 41% F
Risk Adjusted Return 50.49% 41% F 30% F
Market Capitalization 733.69B 92% A 93% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector